Full Text:


Ǵм Vol.24_No.2 Suppl. P.S142-151, Dec. 2007


Ȱȭ ȿ

latelet Activating Factor-Acetylhydrolase

б ǰ ̻б
åڣ, 뱸 5 317-1, б ǰ ̻б
Tel: (053) 620-4362, Fax: (053) 653-6628
E-mail: doxr7p@med.yu.ac.kr

December 30, 2007


Platelet activating factor (PAF) is a phospholipid with a strong inflammatory mediator. PAF is synthesized in a variety of cells in response to inflammatory stimuli. PAF is degraded by intracellular and extracellular PAF-acetylhydrolases (PAF-AHs) thus providing proper level of PAF. Plasma PAF-AH deficiency is associated with several diseases such as asthma, systemic lupus erythematosus, juvenile rheumatoid arthritis, acute myocardial infarction, diabetes, and membranous nephropathy. Cloning of plasma PAF-AH gene enabled the use of recombinant PAF-AH as a therapeutic tool for these PAF-mediated diseases.

Key Words: KeyWords:Platelet activating factor, Platelet activating factor-acetylhydrolase, disease, recombinant, treatment


1. Snyder F. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta 1995; 1254: 231-49.

2. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Intern Med 1995; 238: 5-20.

3. Pinckard RN, Farr RS, Hanahan DJ. Physi- cochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J Immunol 1979; 123: 1847-57.

4. Venable ME, Zimmerman GA, McIntyre TM, Prescott SM. Platelet-activating factor: a phospholipid autacoid with diverse actions. J Lipid Res 1993; 34: 691-702.

5. Izumi T, Shimizu T. Platelet-activating factor receptor: gene expression and signal transduction. Biochim Biophys Acta 1995; 1259: 317-33.

6. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. Platelet-activating factor: antagonists, terminators, molecular mimics, and microbial opportunism. J Intern Med 1996; 239: 463-66.

7. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor- acetylhydrolases (PAF-AH). Prog Lipid Res 2003; 42: 93-114.

8. Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Molecular Events in Acute Inflammation. Arterioscler Thromb Vasc Biol 2002; 22: 727-33.

9. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, et al. Anti- inflammatory properties of a platelet-activating factor acetylhydrolase. Nature (London) 1995; 374: 549-53.

10. Akiyama M, Sugatani J, Suzuki T, Suzuki Y, Miwa M. Identification of a major PAF acetylhydrolase in human serum/plasma as a 43 kDa glycoprotein containing about 9 kDa asparagine-conjugated sugar chain(s). J Biochem (Tokyo) 1998; 123: 786-89.

11. Chen CH. Platelet-activating factor acetylhyd- rolase: is it good or bad for you? Curr Opin Lipidol 2004; 15: 337-41.

12. Hattori M, Arai H, Inoue K. Purification and characterization of bovine brain platelet- activating factor acetylhydrolase. J Biol Chem 1993; 268: 18748-53.

13. Hattori K, Hattori M, Adachi H, Tsujimoto M, Arai H, Inoue K. Purification and Characteri- zation of platelet-activating factor acetylhydrolase II from bovine liver Cytosol. J Biol Chem 1995; 270: 22308-13.

14. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem 1997; 272: 17895-98.

15. Satoh K, Yoshida H, Imaizumi T, Takamatsu S, Mizuno S. Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke Stroke 1992; 23: 1090-92.

16. Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, et al. Purification, properties, sequencing, and cloning of a lipoprotein- associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol 1996; 16: 591-99.

17. Tjoelker LW, Eberhardt C, Unger J, Trong HL, Zimmerman GA, McIntyre TM, et al. Plasma Platelet-activating Factor Acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J Biol Chem 1995; 270: 25481-87.

18. Elstad MR, Stafforini DM, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet activating factor. J Biol Chem 1989; 264: 8467-70.

19. Narahara H, Frenkel RA, Johnston JM. Secretion of platelet-activating factor acetylhy- drolase following phorbol ester-stimulated differentiation of HL-60 cells. Arch Biochem Biophys 1993; 301: 275-81.

20. Howard KM, Olson MS. The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. J Biol Chem 2000; 275: 19891-96.

21. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 1987; 262: 4215-22.

22. Tsukioka K, Matsuzaki M, Nakamata M, Kayahara H, Nakagawa T. Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma. J Investig Allergol Clin Immunol 1996; 6: 22-29.

23. Hofmann B, Ruhling K, Spangenberg P, Ostermann G. Enhanced degradation of platelet-activating factor in serum from diabetic patients. Haemostasis 1989; 19: 180-84.

24. Tetta C, Bussolino F, Modena V, Montrucchio G, Segoloni G, Pescarmona G, et al. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1990; 91: 244-56.

25. Tselepis AD, Elisaf M, Besis S, Karabina SA, Chapman MJ, Siamopoulou A. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein associated platelet-activating factor acetylhydrolase activity. Arhiritis Rheum 1999; 42: 373-83.

26. Partrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC. Reduced PAF-acetylhydrolase activity is associated with postinjury multiple organ failure. Shock 1997; 7: 170-74.

27. Serebruany VL, Gurbel PA, Murugesan SR, Lowry DR, Sturm E, Svetlov SI. Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. Cardiology 1998; 90: 127-30.

28. Graham RM, Stephens CJ, Silvester W, Leong LL, Sturm MJ, Taylor RR. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 1994; 22: 204-12.

29. Kald B, Smedh K, Olaison G, Sjodahl R, Tagesson C. Platelet-activating factor acetylhy- drolase activity in intestinal mucosa and plasma of patients with Crohns disease. Digestion 1996; 57: 472-77.

30. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, et al. Characterization of serum plateletactivating factor (PAF) acetylhy- drolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic chirdren. J Clin Invest 1981; 82: 1983-91.

31. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, et al. Platelet activating factor acetylhydrolase deficiency. A missense mutation near the active site of anti-inflammatory phospholipase. J Clin Invest 1996; 97: 2784-91.

32. Yamada Y, Yokota M. Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281Arg mutation. Biochem Biophys Res Commun 1997; 236: 772-75.

33. Henderson WR Jr, Lu J, Poole KM, Dietsch GN, Chi EY. Recombinant human platelet- activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. J Immunol 2000; 164: 3360-67.

34. Imaizumi T, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Intern Med 1995; 238: 5-20.

35. Fukuda Y, Kawashima H, Saito K, Inomata N, Matsui M, Nakanishi T. Effect of human plasma-type platelet-activating factor acetylhy- drolase in two anaphylactic shock models. Eur J Pharmacol 2000; 390: 203-07.

36. Loucks EB, Symersky P, Qayumi AK. Platelet-activating factor antagonism: a new concept in the management of regional myocardial ischemia-reperfusion injury. J Invest Surg 1997; 10: 321-38.

37. Morgan EN, Boyle Jr. E.M., Yun W., Kovacich J.C., Canty Jr. T.G., Chi E, et al. Platelet activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 1999; 100: 365-68.

38. Nathan N, Denizot Y, Huc MC, Claverie C, Laubie B, Benveniste J, et al. Elevated levels of paf-acether in blood of patients with type I diabetes mellitus. Diabete Metab 1992; 18: 59-62.

39. Lee ES, Jiang J, Sund GC, Simonson WT, Graham J, Dietsch G, et al. Recombinant human platelet-activating factor acetylhydrolase reduces the frequency of diabetes in the diabetes-prone BB rats. Diabetes 1999; 48: 43-49.